Arjun Goyal is listed as a director on 4 SEC Form D filings by 2 issuers between Nov 2021 and May 2023: Quanta Therapeutics, Inc. (South San Francisco, CA — biotechnology — 2021–2023; $76.2M reported sold to 17 investors) and Alterome Therapeutics, Inc. (San Marcos, CA — biotechnology — 2022; $63.8M reported sold to 9 investors).
What this means 2 separate companies raised money with this person listed as director, over about 2 years. Across those companies the filings report $140M sold in total.
Listed alongside Cameron Pitt (3 shared filings), Maha Katabi (3 shared filings), Maria Fardis (3 shared filings), Perry Nisen (3 shared filings), Samuel Saks (3 shared filings) and 6 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Arjun. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, OK, OR, PA, RI, SC, SD, TN, TX, VT, WA, WI, WV, WY) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 4 public filings for Arjun Goyal and found 4 differences, 1 worth asking the sponsor about: Arjun Goyal is no longer listed on the Jun 24, 2026 amendment; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.